openPR Logo
Press release

Lawsuit filed for Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI)

08-01-2019 12:36 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

A lawsuit was filed on behalf of investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares.

A lawsuit was filed on behalf of investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) shares.

An investor, who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI), filed a lawsuit over alleged violations of Federal Securities Laws by Karyopharm Therapeutics Inc.

Investors who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and for certain investors are short and strict deadlines running. Deadline: September 23, 2019. NASDAQ: KPTI investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

Karyopharm Therapeutics Inc is developing small molecule selective inhibitor of nuclear export (SINE) compounds that inhibit the nuclear export protein exportin 1 Its lead compound is XPOVIO (selinexor), which has received approval from the Food and Drug Administration in combination with dexamethasone as a treatment for patients with heavily pretreated multiple myeloma, as well as is under review by the European Medicines Agency.

On February 22, 2019, when the Federal Drug Administration ("FDA") released a briefing document that expressed serious concerns with selinexor. Specifically, the FDA revealed that, contrary to Karyopharm's assurances, one of the previously cancelled selinexor trials had resulted in "worse overall survival" for certain patients treated with selinexor, which "highlight[ed] the toxicity of this drug." The FDA unambiguously concluded that "[t]reatment with selinexor is associated with significant toxicity" and has "limited efficacy."

Shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) declined from $21.71 per share in August 2018 to as low as $3.92 per share on March 1, 2019.

The plaintiff claims violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Karyopharm Therapeutics Inc. (NASDAQ: KPTI) common stock during the time period of March 2, 2017 and February 22, 2019, and violations of Sections 11, 12(a)(2), and 15 of the Securities Act of 1933 on behalf of all persons who purchased or otherwise acquired Karyopharm Therapeutics Inc. (NASDAQ: KPTI common stock in or traceable to the Company's public offerings of common stock conducted on or around April 28, 2017 and May 7, 2018.
More specifically, the plaintiff alleges that the Defendants' material misrepresentations and omissions center on Defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer, that the, Defendants claimed that selinexor studies showed that selinexor was "well-tolerated" by patients and explained that there were "no new clinically significant adverse events in the patients receiving selinexor", and that the Company repeatedly touted the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile”, while in reality, selinexor was unsafe with limited efficacy.

Those who purchased shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) have certain options and should contact the Shareholders Foundation.

Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Lawsuit filed for Investors in shares of Karyopharm Therapeutics Inc. (NASDAQ: KPTI) here

News-ID: 1815938 • Views: 254

More Releases from Shareholders Foundation

Investigation announced for NYSE: COF Investors over possible Wrongdoing at Capi …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Capital One Financial Corporation. Investors who are current long term investors in Capital One Financial Corporation (NYSE: COF) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NYSE: COF stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Acadia Healthcare Company Inc …
An investigation was announced for investors in shares of Acadia Healthcare Company Inc (NASDAQ: ACHC) concerning potential breaches of fiduciary duties by certain directors at Acadia Healthcare Company Inc. Investors who purchased shares of Acadia Healthcare Company Inc (NASDAQ: ACHC) and currently hold any of those NASDAQ: ACHC shares have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Investigation for Investors in shares of PlayAGS, Inc. (NYSE: AGS) announced
An investigation was announced concerning potential securities laws violations by PlayAGS, Inc. in connection with certain financial statements. Investors who purchased shares of PlayAGS, Inc. (NYSE: AGS), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of PlayAGS, Inc. (NYSE: AGS) concerning whether a series of statements
Lawsuit filed for Investors in shares of Spirit AeroSystems Holdings, Inc. (NYSE …
An investor, who purchased shares of Spirit AeroSystems Holdings, Inc. (NYSE: SPR), filed a lawsuit over alleged violations of Federal Securities Laws by Spirit AeroSystems Holdings, Inc. Investors who purchased shares of Spirit AeroSystems Holdings, Inc. (NYSE: SPR) have certain options and for certain investors are short and strict deadlines running. Deadline: April 10, 2020. NYSE: SPR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 -

All 5 Releases


More Releases for Karyopharm

Hematological Cancers Therapeutics Market To Reach $66.34 Billion By 2026 | Top …
According to the current analysis of Reports and Data, the global hematological cancers therapeutics market accounted for USD 31.32 Billion in 2018 and is expected to reach USD 66.34 billion by 2026 , at a CAGR of 9.8 percent. Hematology Cancer Therapeutics market is majorly driven by a high incidence of blood cancer across the globe and favorable funding scenario for the research and development of therapeutics for blood cancer.
Pet Cancer Therapeutics Market Size 2019 by Top Key Players: Aratana Therapeutic …
Market Study Report, LLC, has compiled a detailed study on the Pet Cancer Therapeutics market which provides a brief summary of the growth trends influencing the market. The report also includes significant insights pertaining to the profitability graph, market share, regional proliferation and SWOT analysis of this business vertical. The report further illustrates the status of key players in the competitive setting of the Pet Cancer Therapeutics market, while expanding
New Report Focusing on Pet Cancer Therapeutics Market Growth Study in Detail alo …
Pet cancer therapeutics refers to various therapeutic agents used to treat cancer in pet animals. The success rate of various treatments, preventing and curing neoplasia and cancer in the pet population, has observed a significant rise over the past few years, as a result of the recent advancements in early recognition, diagnosis, and treatment. The growing prevalence of several types of cancers in cats and dogs, as well as increase
Pet Cancer Therapeutics Market Explore Future Growth 2018-2026 by Global Top Pla …
Coherent Market Insights has announced the addition of the “Pet Cancer Therapeutics Market Size Status and Forecast 2026”, The report classifies the global Pet Cancer Therapeutics Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. This report studies the global Pet Cancer Therapeutics Speaker market, analyzes and researches the Pet Cancer Therapeutics Speaker development status and forecast in
Pet Cancer Therapeutics Market 2018 Global Research and Top Manufacturers: Boehr …
Pet Cancer Therapeutics Market report offers the up-to-date industry information and enterprise future developments, allowing you to recognize the goods and end customers driving sales increase and profitability. This pet cancer therapeutics report consists of the forecasts up to 2023, analysis and dialogue of important enterprise developments, market length, market share estimates and profiles of the leading industry players. The worldwide market for Pet Cancer Therapeutics is expected to grow at
Pet Cancer Therapeutics Market Explore Future Growth 2017-2025 by Global Top Pla …
Coherent Market Insights has announced the addition of the “Pet Cancer Therapeutics Market Size Status and Forecast 2026”, The report classifies the global Pet Cancer Therapeutics Market in a precise manner to offer detailed insights about the aspects responsible for augmenting as well as restraining market growth. This report studies the global Pet Cancer Therapeutics Speaker market, analyzes and researches the Pet Cancer Therapeutics Speaker development status and forecast in